OPTN vs. SCTL, RZLT, RLMD, CLRB, PMVP, COYA, RNAC, CTXR, IMUX, and ALLK
Should you be buying OptiNose stock or one of its competitors? The main competitors of OptiNose include Societal CDMO (SCTL), Rezolute (RZLT), Relmada Therapeutics (RLMD), Cellectar Biosciences (CLRB), PMV Pharmaceuticals (PMVP), Coya Therapeutics (COYA), Cartesian Therapeutics (RNAC), Citius Pharmaceuticals (CTXR), Immunic (IMUX), and Allakos (ALLK). These companies are all part of the "pharmaceutical preparations" industry.
OptiNose (NASDAQ:OPTN) and Societal CDMO (NASDAQ:SCTL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking and institutional ownership.
85.6% of OptiNose shares are held by institutional investors. Comparatively, 87.2% of Societal CDMO shares are held by institutional investors. 2.2% of OptiNose shares are held by company insiders. Comparatively, 7.6% of Societal CDMO shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Societal CDMO has a net margin of -14.03% compared to OptiNose's net margin of -50.06%. OptiNose's return on equity of 0.00% beat Societal CDMO's return on equity.
OptiNose currently has a consensus price target of $4.00, indicating a potential upside of 241.88%. Societal CDMO has a consensus price target of $1.80, indicating a potential upside of 63.64%. Given OptiNose's stronger consensus rating and higher possible upside, research analysts clearly believe OptiNose is more favorable than Societal CDMO.
OptiNose has a beta of -0.1, meaning that its share price is 110% less volatile than the S&P 500. Comparatively, Societal CDMO has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.
OptiNose received 235 more outperform votes than Societal CDMO when rated by MarketBeat users. However, 80.00% of users gave Societal CDMO an outperform vote while only 63.12% of users gave OptiNose an outperform vote.
Societal CDMO has higher revenue and earnings than OptiNose. Societal CDMO is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks.
In the previous week, OptiNose had 10 more articles in the media than Societal CDMO. MarketBeat recorded 10 mentions for OptiNose and 0 mentions for Societal CDMO. OptiNose's average media sentiment score of 0.17 beat Societal CDMO's score of 0.00 indicating that OptiNose is being referred to more favorably in the media.
Summary
OptiNose and Societal CDMO tied by winning 9 of the 18 factors compared between the two stocks.
Get OptiNose News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPTN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OptiNose Competitors List
Related Companies and Tools
